Type 2 diabetes mellitus is a multiorgan, metabolic disease associated with multiple microvascular and macrovascular complications. The incidence of type 2 diabetes is growing at an alarming rate. Achieving and maintaining near-normal blood glucose and glycosylated hemoglobin levels (A1C) are of the utmost importance. Existing treatment options for managing type 2 diabetes, which have primarily included sulfonylureas and biguanides, are insufficient at achieving these treatment goals alone, particularly if used long term. The need to explore newer and better treatment options that provide longer lasting glucose control and at the same time focus on targeting cardiovascular risk factors to minimize and prevent the serious complications associated with this multifaceted disease becomes quite obvious.
Get full access to this article
View all access options for this article.
References
1.
1. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998 . Diabetes Care. 2000;23: 1278-1283 .
2.
2. Diabetes Research Working Group. Summary of the report and recommendations of the congressionally-established Diabetes Research Working Group: a strategic plan for the 21st century. 1999. Retrieved September 10, 2003, from http://www.jdfcure.org/drwg/.
3.
3. Mitzner L. Selecting the best medication for type 2 diabetes . Cortlandt Forum. 2003;16(8): 16-19 .
4.
4. Weyer C, Bogardus C, Mott D, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus . J Clin Invest. 1999;104(6): 787-794 .
5.
5. Wyne KL. The need for reappraisal of type 2 diabetes mellitus management . Postgrad Med. 2003;8: 5-14 .
6.
6. Anderson RM, Funnell MM. The Art of Empowerment: Stories and Strategies for Diabetes Educators. Alexandria, VA: American Diabetes Association ; 2000.
7.
7. Reddan LP, et al. Nutrition, obesity and exercise. In: Lifescan Diabetes Programs. Pharmacy Partners in Diabetes Care. 2nd ed. Philadelphia, Pa: CoMed Communications, Inc ; 2000:2-18.
8.
8. FranzMJ, Kulkarni K, Daly AS, et al. Therapies: nutrition. In: A Core Curriculum for Diabetes Education. 3rd ed. Chicago, Ill: American Association of Diabetes Educators ; 1998: 189-256.
9.
9. Peragallo-Dittko V. Therapies: monitoring. In: A Core Curriculum for Diabetes Education. 3rd ed. Chicago, Ill: American Association of Diabetes Educators ; 1998:361-383.
10.
10. Kistler JA. Therapies: exercise. In: A Core Curriculum for Diabetes Education. 3rd ed. Chicago, Ill: American Association ofDiabetes Educators ; 1998:257-296.
22. Wyne KL, Drexler AJ, Miller JL, et al. Constructing an algorithm for managing type 2 diabetes: focus on the role of the thiazolidinediones . Postgrad Med. 2003;8: 63-72 .
23.
23. Bell DS, Leahy JL, Piziak VK. Achieving glycemic control with insulin in type 2 diabetes . Patient Care. 2002;10: 59-84 .
24.
24. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes . Endocrinol Metab Clin North Am. 2001;30: 935-982 .
